GoodRx’s Post

1. Novo Nordisk's Ozempic has received FDA approval for use in treating kidney disease. 2. The drug is now indicated for reducing the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease. 3. Ozempic (semaglutide) is now the most broadly indicated GLP-1 drug available. 4. It was previously approved for weight loss under the brand name Wegovy in 2021. 5. The European Medicines Agency supports the expanded label for Ozempic based on a trial showing a 24% reduction in kidney disease-related events in diabetic patients.

🌬️ Sharing my seminar topic ppt on "The Pharmacotherapy of Asthma and COPD" given to Dr. Syed Salman Ali Dive into the detailed presentation on SlideShare to explore the latest insights and therapeutic approaches. Whether you're a fellow scholar, healthcare professional, or just curious about the advancements in respiratory treatments, this is for you! Check out the full presentation here: https://lnkd.in/gAhGpTCT #Pharmacotherapy #Asthma #COPD #Healthcare #Pharmacology #Toxicology #MedicalResearch

Great news 👏 Novo Nordisk announces that the FDA has granted approval to its blockbuster drug Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes. Ozempic can now be used to lower the risk of CKD progression, kidney failure, and cardiovascular-related death in that patient population.#kidneydisease #Semaglutide #diabetes #type2diabetes #nephropathy #GLP-1 👇👇 https://lnkd.in/e_uN72Tk

Thoughts on this? >> Silence’s siRNA candidate for cardiovascular disease continues to deliver in Phase 2 trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical

Today marks World Asthma Day, a day to raise awareness about asthma and support those affected by the condition. Asthma is a life-long condition that causes airways to become inflamed and narrow, making it difficult to breathe and can be life-threatening. With proper treatment, asthma patients will have less symptoms and can live normal and active lives[1]. Together, we can advocate for early diagnosis, better asthma management, increased research, and improved access to treatment. Let's work together to ensure that everyone with asthma receives the support they need to live healthy and active lives. 💙 #accord #healthcare #pharmaceuticals #globalhealth #biosimilar #medicine #worldasthmaday #asthma References: 1. https://lnkd.in/dbnsDyhu

FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use by Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

#Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease. The drug was cleared for use in adults whose COPD symptoms aren’t under control and whose disease is driven by eosinophils, a type of immune cell that can contribute to inflammation. There are 300,000 such people in the U.S., according to Regeneron and Sanofi, which jointly developed Dupixent. Market analysts estimate the new indication could bring in more than $1 billion in additional annual revenue for Dupixent. The drug has a list price of $3,803 for a one-month supply. Full story: https://trib.al/BBJDyEx

🌟 Major Milestone for Diabetes Care and Kidney Health 🌟 Novo Nordisk's Ozempic (semaglutide) has received a key endorsement from European regulators, expanding its label to highlight its ability to reduce kidney risks in adults with Type 2 diabetes. 🔍 Key Insights: Clinical Impact: Ozempic has shown significant results in slowing the progression of chronic kidney disease, while also reducing the risks of kidney failure, heart attack, stroke, and mortality in people with Type 2 diabetes. Broader Implications: This marks a pivotal step in addressing the interconnected risks of diabetes and kidney disease, offering patients a more comprehensive approach to long-term health management. This endorsement underscores the critical role of innovation in diabetes care and highlights the importance of integrating cardiometabolic and renal outcomes in treatment strategies. 💡 As someone passionate about advancing therapies in diabetes and chronic disease management, it’s inspiring to see breakthroughs like this shaping the future of healthcare. 🔗 Read more: https://lnkd.in/gz3biCSA #DiabetesCare #KidneyHealth #NovoNordisk #PharmaceuticalInnovation #ChronicDiseaseManagement #Healthcare

#FDA approves Miplyffa™ (arimoclomol) for Niemann-Pick disease type C (NPC) in combination with miglustat, marking the first FDA-approved treatment for NPC. Recommended for adults & kids aged 2+, it targets neurological symptoms. Available in 8-12 weeks. https://lnkd.in/eQEfUNpi #Miplyffa #NiemannPickDisease

💊 Metformin or Ozempic? 🤔 Both can help manage diabetes, but they work differently. Metformin is often the first choice, while Ozempic can help with blood sugar and weight loss. 🌡️ Did you know Ozempic can reduce A1C levels by up to 1.5%? Learn more about these medications! 💡 #firstchoice #managediabetes #workdifferently #weightloss #work #reduce #level Read the full article now👉https://loom.ly/KBw9scU